Inavolisib, palbociclib, letrozole clinical trials

A study to assess the safety and effectiveness of inavolisib plus a cdk4/6 inhibitor and letrozole versus placebo plus a CDK4/6 inhibitor and letrozole in participants with advanced breast cancer

This study looks at a new drug, inavolisib, for advanced breast cancer that has a specific genetic change (PIK3CA mutation). It compares inavolisib combined with standard treatments (palbociclib and letrozole) to a dummy drug plus the standard treatments. The goal is to see if inavolisib is safe and works better.